THC Tenet Healthcare

Filed: 10 Aug 21, 7:00am





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: August 5, 2021

(Date of earliest event reported)




(Exact name of Registrant as specified in its charter)




Nevada 1-7293 95-2557091
(State of Incorporation) 


File Number)


(IRS Employer

Identification Number)

14201 Dallas Parkway

Dallas, TX 75254

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common stock, $0.05 par value THC NYSE
6.875% Senior Notes due 2031 THC31 NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.  ☐




Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 9, 2021, Tenet Healthcare Corporation (the “Company”) announced that, in furtherance of the Company’s long-term succession plan, Ronald A. Rittenmeyer will transition from Chief Executive Officer of the Company and continue as the Executive Chairman of the Company and the Board of Directors of the Company through 2022, and Saumya Sutaria, M.D., will be promoted from President and Chief Operating Officer of the Company to the Chief Executive Officer of the Company, in each case effective as of September 1, 2021. Dr. Sutaria will continue to report to Mr. Rittenmeyer. The Board of Directors of the Company approved the transition on August 5, 2021.

The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K with respect to Dr. Sutaria is included in the Company’s annual proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2021, and is hereby incorporated by reference herein.


Item 7.01

Regulation FD Disclosure.

A copy of the press release announcing the matters described above is attached to this report as Exhibit 99.1 and incorporated herein by reference. The information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits





99.1  Press Release issued on August 9, 2021
104  Cover Page Interactive Data File (embedded within the inline XBRL document)


- 2 -


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Date: August 10, 2021  By: 

/s/ Thomas Arnst

  Name: Thomas Arnst

Executive Vice President, Chief

Administrative Officer and General Counsel


- 3 -